TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 20832060

Group type: EXPERIMENTAL
Intervention: Statistical word segmentation experiments with varying sentence lengths, exposure amounts, and word counts
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Probabilistic models of segmentation
Number of subjects: 0
Study: 18266651

Group type: EXPERIMENTAL
Intervention: Viewing humorous films
Number of subjects: 36

Group type: COMPARATOR
Intervention: Control nonhumorous weather information films
Number of subjects: 36

Group type: EXPERIMENTAL
Intervention: Viewing humorous films after control films
Number of subjects: 36

Group type: COMPARATOR
Intervention: Control films followed by humorous films
Number of subjects: 36
Study: 16630986

Group type: EXPERIMENTAL
Intervention: Oral rapamycin (6 mg loading dose followed by 3 mg/day for 14 days)
Number of subjects: 100
Study: 15197517

Group type: COMPARATOR
Intervention: Nateglinide alone (120 mg)
Number of subjects: 18

Group type: EXPERIMENTAL
Intervention: Nateglinide with sulfinpyrazone (400 mg/day for 7 days)
Number of subjects: 18
Study: 11074103

Group type: COMPARATOR
Intervention: Lithium (N=15), administered twice daily in doses varying from 1050 to 1950 mg (mean=1569 mg) for 3 weeks.
Number of subjects: 30

Group type: COMPARATOR
Intervention: Placebo (N=15), administered for 3 weeks.
Number of subjects: 30
Study: 9091474

Group type: EXPERIMENTAL
Intervention: Cyclosporine 3.0 mg/kg per day
Number of subjects: 181

Group type: EXPERIMENTAL
Intervention: Cyclosporine 1.5 mg/kg per day
Number of subjects: 181

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 181

Group type: EXPERIMENTAL
Intervention: Cyclosporine 5.0 mg/kg per day (induction phase)
Number of subjects: 181
Study: 8295188

Group type: EXPERIMENTAL
Intervention: tiaprofenic acid
Number of subjects: 208

Group type: EXPERIMENTAL
Intervention: naproxen
Number of subjects: 208
Study: 3305355

Group type: EXPERIMENTAL
Intervention: Diet and behavior change group
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: Diet, behavior change, and exercise group
Number of subjects: 50

Group type: COMPARATOR
Intervention: Obese control group
Number of subjects: 50
Study: 29320553

Group type: EXPERIMENTAL
Intervention: Undiagnosed abnormal postpartum blood loss (UPPBL)
Number of subjects: 3917

Group type: EXPERIMENTAL
Intervention: Postpartum haemorrhage (PPH)
Number of subjects: 3917

Group type: EXPERIMENTAL
Intervention: UPPBL
Number of subjects: 3917

Group type: EXPERIMENTAL
Intervention: PPH
Number of subjects: 3917

Group type: EXPERIMENTAL
Intervention: Both UPPBL and PPH
Number of subjects: 3917
Study: 26886470

Group type: EXPERIMENTAL
Intervention: Program for the Education and Enrichment of Relational Skills (PEERS)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Waitlist group (control)
Number of subjects: 0
Study: 25098487

Group type: EXPERIMENTAL
Intervention: GP-led triage
Number of subjects: 20990

Group type: EXPERIMENTAL
Intervention: Nurse-led triage
Number of subjects: 20990

Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 20990
Study: 22852580

Group type: EXPERIMENTAL
Intervention: BRN-01 tablets (homeopathic medicine containing Actaea racemosa, Arnica montana, Glonoinum, Lachesis mutus, Sanguinaria canadensis)
Number of subjects: 108

Group type: COMPARATOR
Intervention: Placebo tablets
Number of subjects: 108

Group type: EXPERIMENTAL
Intervention: BRN-01 tablets
Number of subjects: 108
Study: 20598970

Group type: EXPERIMENTAL
Intervention: Implantation of the subcutaneous cardiac monitor (Reveal XT; Medtronic, Inc, Minneapolis, MN)
Number of subjects: 450

Group type: COMPARATOR
Intervention: Standard arrhythmia monitoring (control arm)
Number of subjects: 450
Study: 18606966

Group type: EXPERIMENTAL
Intervention: Botulinum toxin A (Dysport) treatment
Number of subjects: 64

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 64
Study: 15818323

Group type: EXPERIMENTAL
Intervention: Dac/Tac/MMF
Number of subjects: 538

Group type: COMPARATOR
Intervention: Tac/MMF/corticosteroids
Number of subjects: 538
Study: 12613687

Group type: EXPERIMENTAL
Intervention: Higher average backward associative strength (BAS) list items presented by speakers.
Number of subjects: 0

Group type: COMPARATOR
Intervention: Lower average backward associative strength (BAS) list items presented by speakers.
Number of subjects: 0
Study: 10334023

Group type: EXPERIMENTAL
Intervention: Trabeculectomy with intraoperative mitomycin-C (MMC)
Number of subjects: 25

Group type: COMPARATOR
Intervention: Standard trabeculectomy without MMC
Number of subjects: 25
Study: 8877019

Group type: EXPERIMENTAL
Intervention: 1 mg nalmefene in young subjects (n=18)
Number of subjects: 52

Group type: EXPERIMENTAL
Intervention: 1 mg nalmefene in elderly subjects (n=11)
Number of subjects: 52

Group type: EXPERIMENTAL
Intervention: 2 mg nalmefene in young subjects (n=8)
Number of subjects: 52

Group type: EXPERIMENTAL
Intervention: 2 mg nalmefene in elderly subjects (n=15)
Number of subjects: 52
Study: 2020040

Group type: EXPERIMENTAL
Intervention: Antacids
Number of subjects: 89

Group type: COMPARATOR
Intervention: Continuous IV cimetidine
Number of subjects: 89

Group type: COMPARATOR
Intervention: Sucralfate
Number of subjects: 89
Study: 6122890

Group type: EXPERIMENTAL
Intervention: Intramuscular vitamin E
Number of subjects: 126

Group type: COMPARATOR
Intervention: Control
Number of subjects: 126
Study: 30365368

Group type: EXPERIMENTAL
Intervention: Symptom Free Days Questionnaire (SFDQ)
Number of subjects: 1070
Study: 27909047

Group type: EXPERIMENTAL
Intervention: Walking exercise program
Number of subjects: 296

Group type: COMPARATOR
Intervention: Normal physical activity (control)
Number of subjects: 296
Study: 27652041

Group type: EXPERIMENTAL
Intervention: PBC & RBS herbal medicine
Number of subjects: 360

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 360
Study: 25191937

Group type: EXPERIMENTAL
Intervention: ICSI/PGS treatment
Number of subjects: 215

Group type: COMPARATOR
Intervention: Standard ICSI treatment
Number of subjects: 215
Study: 22182496

Group type: EXPERIMENTAL
Intervention: Cardiac resynchronization therapy (CRT) with atrioventricular optimization (AVO) via SmartDelay or echocardiography
Number of subjects: 846

Group type: EXPERIMENTAL
Intervention: Atrioventricular optimization (AVO)
Number of subjects: 846
Study: 20517484

Group type: EXPERIMENTAL
Intervention: Rasagiline 1 mg/day
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Rasagiline (as monotherapy in early PD and adjunctive therapy in advanced PD)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Rasagiline
Number of subjects: 0
Study: 17645805

Group type: EXPERIMENTAL
Intervention: Nurse-led intervention to increase physical activity with a 'Lifestyle script' and telephone counselling for nine months, plus a face-to-face nurse visit at six months
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Nurse-led intervention
Number of subjects: 0
Study: 16129010

Group type: EXPERIMENTAL
Intervention: Mutual support group (n = 32)
Number of subjects: 96

Group type: COMPARATOR
Intervention: Psycho-educational group (n = 33)
Number of subjects: 96

Group type: COMPARATOR
Intervention: Standard care only (n = 31)
Number of subjects: 96
Study: 12351443

Group type: EXPERIMENTAL
Intervention: Insulin treatment (hyperinsulinemic-euglycemic clamps at 1, 2, and 4 mU x min(‐1) x kg(‐1)) for 67 hours
Number of subjects: 14

Group type: COMPARATOR
Intervention: Nondiabetic control subjects
Number of subjects: 14
Study: 10419923

Group type: EXPERIMENTAL
Intervention: IFN-ribavirin (3 MU three times weekly + 1-1.2 g ribavirin daily for 6 months)
Number of subjects: 344

Group type: COMPARATOR
Intervention: IFN monotherapy (3 MU three times weekly for 6 months)
Number of subjects: 344
Study: 7593730

Group type: EXPERIMENTAL
Intervention: moclobemide (450 mg/day) plus thioridazine (100 mg/day)
Number of subjects: 78

Group type: COMPARATOR
Intervention: moclobemide (450 mg/day) plus placebo
Number of subjects: 78
Study: 2147500

Group type: EXPERIMENTAL
Intervention: Cefotetan 1 g intravenously
Number of subjects: 266

Group type: COMPARATOR
Intervention: Placebo solution
Number of subjects: 266
Study: 6406472

Group type: EXPERIMENTAL
Intervention: Bupropion (300-600 mg/day)
Number of subjects: 75

Group type: EXPERIMENTAL
Intervention: Bupropion
Number of subjects: 75

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 75
Study: 29912723

Group type: EXPERIMENTAL
Intervention: Balanced crystalloid
Number of subjects: 53

Group type: COMPARATOR
Intervention: 0.9% saline solution
Number of subjects: 53

Group type: EXPERIMENTAL
Intervention: Balanced crystalloid and 0.9% saline solution
Number of subjects: 53
Study: 30345312

Group type: EXPERIMENTAL
Intervention: Curcumin-Galactomannoside Complex (CGM) at 250 mg × 2/day for 8 weeks
Number of subjects: 48

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 48
Study: 27623769

Group type: EXPERIMENTAL
Intervention: Higher site enrollment (>60 patients/site)
Number of subjects: 7141

Group type: EXPERIMENTAL
Intervention: Higher site enrollment
Number of subjects: 7141
Study: 24879143

Group type: COMPARATOR
Intervention: Laparoscopic cholecystectomy with energized dissection (ED)
Number of subjects: 745

Group type: EXPERIMENTAL
Intervention: Laparoscopic cholecystectomy with cold dissection (CD)
Number of subjects: 745
Study: 22180393

Group type: EXPERIMENTAL
Intervention: Iyengar yoga intervention
Number of subjects: 31

Group type: COMPARATOR
Intervention: Health education (control)
Number of subjects: 31
Study: 19329014

Group type: EXPERIMENTAL
Intervention: Fentanyl
Number of subjects: 48

Group type: EXPERIMENTAL
Intervention: Sufentanil
Number of subjects: 48

Group type: COMPARATOR
Intervention: Control
Number of subjects: 48
Study: 20089009

Group type: EXPERIMENTAL
Intervention: Rivastigmine transdermal patch (4.6 mg/24 hr)
Number of subjects: 592

Group type: COMPARATOR
Intervention: Rivastigmine capsules (3-12 mg/day)
Number of subjects: 592
Study: 15549297

Group type: EXPERIMENTAL
Intervention: FDG-PET
Number of subjects: 77
Study: 11862364

Group type: EXPERIMENTAL
Intervention: 4 mg reboxetine
Number of subjects: 36

Group type: EXPERIMENTAL
Intervention: 8 mg reboxetine
Number of subjects: 36

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 36
Study: 9857272

Group type: EXPERIMENTAL
Intervention: Comprehensive cardiac rehabilitation program (CR+) for 2 months including an extensive educational program on cardiovascular risk factors, lipids, and diet
Number of subjects: 52

Group type: COMPARATOR
Intervention: No cardiac rehabilitation (CR-)
Number of subjects: 52
Study: 7712618

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 3337027

Group type: EXPERIMENTAL
Intervention: Bovine serum albumin
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Beef meat
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Egg white
Number of subjects: 0
Study: 29671041

Group type: EXPERIMENTAL
Intervention: Chlorhexidine gluconate (0.12% oropharyngeal rinse and 4% nasopharyngeal soap)
Number of subjects: 450

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 450
Study: 27687394

Group type: EXPERIMENTAL
Intervention: Mechanical ventilation parameters with f=9 beats per minute, VT=8 mL/kg, I:E=1:2.0
Number of subjects: 27

Group type: EXPERIMENTAL
Intervention: Mechanical ventilation parameters with different combinations of f, VT, and I:E
Number of subjects: 27

Group type: EXPERIMENTAL
Intervention: Mechanical ventilation parameters with changes in f, VT, and I:E
Number of subjects: 27

Group type: EXPERIMENTAL
Intervention: Mechanical ventilation parameters with selected respiratory parameters
Number of subjects: 27
Study: 24117808

Group type: COMPARATOR
Intervention: Complementary foods from 4 months of age (CF)
Number of subjects: 119

Group type: EXPERIMENTAL
Intervention: Exclusive breastfeeding for 6 months (EBF)
Number of subjects: 119
Study: 22858430

Group type: EXPERIMENTAL
Intervention: Intravenous landiolol at 5 μg/kg/min for 3 days (group L)
Number of subjects: 105

Group type: EXPERIMENTAL
Intervention: Oral bisoprolol postoperatively with landiolol (group LB)
Number of subjects: 105

Group type: COMPARATOR
Intervention: Control group without beta-blocker therapy (group C)
Number of subjects: 105

Group type: COMPARATOR
Intervention: Control group (group C)
Number of subjects: 105
Study: 20532141

Group type: EXPERIMENTAL
Intervention: Intravitreal bevacizumab injection (IVBI) 1.25 mg/0.05 mL
Number of subjects: 24

Group type: COMPARATOR
Intervention: Observation (Control)
Number of subjects: 24
Study: 18681757

Group type: EXPERIMENTAL
Intervention: Quetiapine (N = 42)
Number of subjects: 80

Group type: EXPERIMENTAL
Intervention: Risperidone (N = 38)
Number of subjects: 80

Group type: EXPERIMENTAL
Intervention: Both medications
Number of subjects: 80
Study: 15705599

Group type: EXPERIMENTAL
Intervention: Supplementation with beta‐carotene, vitamins C and E along with zinc (ACEZn) for 6 months
Number of subjects: 190

Group type: COMPARATOR
Intervention: Highest tertile of intake of vitamin E
Number of subjects: 190

Group type: COMPARATOR
Intervention: Highest tertile of intake of retinol
Number of subjects: 190

Group type: COMPARATOR
Intervention: Highest tertile of intake of folic acid
Number of subjects: 190

Group type: COMPARATOR
Intervention: Highest tertile of intake of nicotinic acid (preformed)
Number of subjects: 190

Group type: COMPARATOR
Intervention: Highest tertile of intake of calcium
Number of subjects: 190

Group type: COMPARATOR
Intervention: Highest tertile of intake of riboflavin
Number of subjects: 190

Group type: COMPARATOR
Intervention: Highest tertile of intake of pantothenic acid
Number of subjects: 190

Group type: COMPARATOR
Intervention: Highest tertile of intake of biotin
Number of subjects: 190

Group type: COMPARATOR
Intervention: Mid‐tertile beta‐carotene intake
Number of subjects: 190

Group type: COMPARATOR
Intervention: Highest tertile of beta‐carotene intake (>6400 microg/day)
Number of subjects: 190

Group type: COMPARATOR
Intervention: Increased calcium intake
Number of subjects: 190

Group type: COMPARATOR
Intervention: Increased riboflavin intake
Number of subjects: 190
Study: 12585582

Group type: EXPERIMENTAL
Intervention: Aberdeen Colles' fracture brace
Number of subjects: 339

Group type: COMPARATOR
Intervention: Conventional Colles' plaster cast
Number of subjects: 339
Study: 10388248

Group type: EXPERIMENTAL
Intervention: Lidocaine 0.5 mg/kg/h
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: Lidocaine 2.5 mg/kg/h
Number of subjects: 24

Group type: COMPARATOR
Intervention: Normal saline (placebo)
Number of subjects: 24
Study: 8739822

Group type: EXPERIMENTAL
Intervention: Quinidine bisulphate (250 mg)
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Chlorpromazine hydrochloride (100 mg) with quinidine
Number of subjects: 10

Group type: COMPARATOR
Intervention: Chlorpromazine hydrochloride (100 mg) without quinidine (control)
Number of subjects: 10
Study: 2070143

Group type: EXPERIMENTAL
Intervention: Bladder irrigation
Number of subjects: 34

Group type: COMPARATOR
Intervention: No bladder irrigation
Number of subjects: 34
Study: 6129367

Group type: EXPERIMENTAL
Intervention: Sodium DL‐3‐hydroxybutyrate administered during a 2.5 MJ (600 kcal) diet with 34 g protein and total fast (water and vitamins only) on alternate days for 21 days
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Sodium DL‐3‐hydroxybutyrate administered during therapeutic starvation for 14 days
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Sodium DL‐3‐hydroxybutyrate
Number of subjects: 0
Study: 31525069

Group type: EXPERIMENTAL
Intervention: Reduced LVEF (<50%)
Number of subjects: 2991

Group type: EXPERIMENTAL
Intervention: LVEF as continuous variable
Number of subjects: 2991
Study: 29221978

Group type: EXPERIMENTAL
Intervention: 6% HES 130/0.4
Number of subjects: 44

Group type: COMPARATOR
Intervention: Crystalloid solutions
Number of subjects: 44
Study: 27603788

Group type: EXPERIMENTAL
Intervention: Sunitinib therapy
Number of subjects: 275
Study: 24471663

Group type: EXPERIMENTAL
Intervention: Intravenous paracetamol 2 g
Number of subjects: 240

Group type: EXPERIMENTAL
Intervention: Intravenous parecoxib 40 mg
Number of subjects: 240

Group type: EXPERIMENTAL
Intervention: Combination of intravenous paracetamol 2 g and intravenous parecoxib 40 mg
Number of subjects: 240

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 240
Study: 22937736

Group type: EXPERIMENTAL
Intervention: Amoxicillin‐clavulanic acid (22.5 mg/kg twice daily) with placebo‐azithromycin
Number of subjects: 189

Group type: EXPERIMENTAL
Intervention: Azithromycin (5 mg/kg daily) with placebo‐amoxicillin‐clavulanic acid
Number of subjects: 189

Group type: COMPARATOR
Intervention: Placebo‐azithromycin with placebo‐amoxicillin‐clavulanic acid
Number of subjects: 189

Group type: EXPERIMENTAL
Intervention: Not specified
Number of subjects: 189
Study: 19895619

Group type: EXPERIMENTAL
Intervention: Treatment for major depression over 18 months
Number of subjects: 149

Group type: EXPERIMENTAL
Intervention: Treatment for major depression
Number of subjects: 149
Study: 18093298

Group type: EXPERIMENTAL
Intervention: Passive movement therapy (PMT) given three times a week for four weeks.
Number of subjects: 0

Group type: COMPARATOR
Intervention: Usual care without PMT
Number of subjects: 0
Study: 16253086

Group type: EXPERIMENTAL
Intervention: Chlorhexidine (CHX) spray
Number of subjects: 51

Group type: EXPERIMENTAL
Intervention: Benzydamine hydrochloride (B‐HCl) spray
Number of subjects: 51

Group type: EXPERIMENTAL
Intervention: Chlorhexidine plus Benzydamine hydrochloride (CHX/B‐HCl) spray
Number of subjects: 51
Study: 11344426

Group type: EXPERIMENTAL
Intervention: Dissection balloon
Number of subjects: 322

Group type: COMPARATOR
Intervention: No dissection balloon
Number of subjects: 322
Study: 9701431

Group type: EXPERIMENTAL
Intervention: Metered Dose Inhaler (MDI) with Aerochamber
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Ultrasonic Nebulizer
Number of subjects: 20

Group type: COMPARATOR
Intervention: Jet Nebulizers
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: MDI with Aerochamber
Number of subjects: 20
Study: 8026055

Group type: EXPERIMENTAL
Intervention: Invasive postlytic strategy
Number of subjects: 3339

Group type: COMPARATOR
Intervention: Conservative postlytic strategy
Number of subjects: 3339
Study: 2767766

Group type: EXPERIMENTAL
Intervention: Doxycycline 0.2 g with 300 ml of fresh milk
Number of subjects: 9

Group type: COMPARATOR
Intervention: Doxycycline 0.2 g with 300 ml of water
Number of subjects: 9
Study: 48832

Group type: EXPERIMENTAL
Intervention: Educational programme aimed at instructing about hypertension and its treatment
Number of subjects: 230

Group type: EXPERIMENTAL
Intervention: Follow-up with family doctors outside working-hours
Number of subjects: 230

Group type: COMPARATOR
Intervention: Follow-up with industrial physicians during work shifts
Number of subjects: 230
Study: 31786721

Group type: EXPERIMENTAL
Intervention: Basal diet supplemented with 1% Ascophyllum nodosum algae extract (AN1)
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: Basal diet supplemented with 2% Ascophyllum nodosum algae extract (AN2)
Number of subjects: 24

Group type: COMPARATOR
Intervention: Control diet (AN0)
Number of subjects: 24
Study: 28797188

Group type: EXPERIMENTAL
Intervention: Psoriasis Symptoms and Signs Diary (PSSD)
Number of subjects: 0
Study: 27875291

Group type: EXPERIMENTAL
Intervention: Teduglutide 0.05 mg/kg/d
Number of subjects: 134
Study: 25533966

Group type: EXPERIMENTAL
Intervention: NO3(‐) supplementation (12.9 mmol of NO3‐rich beetroot juice)
Number of subjects: 17
Study: 23044089

Group type: EXPERIMENTAL
Intervention: Psychotherapeutic treatment
Number of subjects: 0
Study: 22103578

Group type: EXPERIMENTAL
Intervention: Implicit goal primes followed by achievement threats
Number of subjects: 444

Group type: EXPERIMENTAL
Intervention: Implicit goal primes followed by relationship threats
Number of subjects: 444

Group type: COMPARATOR
Intervention: Opportunity to attribute anxiety to a mundane source
Number of subjects: 444
Study: 19723679

Group type: EXPERIMENTAL
Intervention: Pro-juven progesterone cream, 20 mg twice daily
Number of subjects: 131

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 131
Study: 17784896

Group type: EXPERIMENTAL
Intervention: Unobserved dosing of buprenorphine-naloxone for 3 months
Number of subjects: 119

Group type: COMPARATOR
Intervention: Observed dosing of buprenorphine-naloxone for 3 months
Number of subjects: 119

Group type: EXPERIMENTAL
Intervention: Unobserved dosing of buprenorphine-naloxone
Number of subjects: 119

Group type: COMPARATOR
Intervention: Observed dosing of buprenorphine-naloxone
Number of subjects: 119
Study: 15569116

Group type: EXPERIMENTAL
Intervention: Bifidobacteria-fermented milk (100 mL/day for 12 weeks)
Number of subjects: 20

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 20
Study: 11737814

Group type: EXPERIMENTAL
Intervention: 20% glycerine
Number of subjects: 109

Group type: EXPERIMENTAL
Intervention: 4% urea (combined with 4% sodium chloride)
Number of subjects: 109

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 109
Study: 9189307

Group type: EXPERIMENTAL
Intervention: T75 (75% VO2max)
Number of subjects: 8

Group type: COMPARATOR
Intervention: T55 (55% VO2max)
Number of subjects: 8
Study: 8130541

Group type: EXPERIMENTAL
Intervention: Quality scoring method
Number of subjects: 19
Study: 3107115

Group type: EXPERIMENTAL
Intervention: Lidocaine (loading dose: 3 mg/kg body weight in 10 min; maintenance dose: 1 mg/kg in 20 min)
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Tocainide infusion (750 mg in 30 min)
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Tocainide orally (400 to 2,400 mg per day)
Number of subjects: 40

Group type: COMPARATOR
Intervention: Saline (placebo)
Number of subjects: 40
Study: 31735121

Group type: EXPERIMENTAL
Intervention: Economic support (Cash Transfer schemes)
Number of subjects: 0
Study: 29044861

Group type: EXPERIMENTAL
Intervention: Dabigatran 110 mg
Number of subjects: 18113

Group type: EXPERIMENTAL
Intervention: Dabigatran 150 mg
Number of subjects: 18113

Group type: COMPARATOR
Intervention: Warfarin
Number of subjects: 18113

Group type: EXPERIMENTAL
Intervention: HAS-BLED score
Number of subjects: 18113

Group type: EXPERIMENTAL
Intervention: ORBIT score
Number of subjects: 18113

Group type: EXPERIMENTAL
Intervention: ATRIA score
Number of subjects: 18113

Group type: EXPERIMENTAL
Intervention: HEMORR2 HAGES score
Number of subjects: 18113
Study: 26519007

Group type: EXPERIMENTAL
Intervention: Etanercept
Number of subjects: 41
Study: 25115201

Group type: EXPERIMENTAL
Intervention: Portable Electronic Vision Enhancement System (p-EVES)
Number of subjects: 100

Group type: COMPARATOR
Intervention: Conventional optical low vision aids (LVAs)
Number of subjects: 100
Study: 22375577

Group type: EXPERIMENTAL
Intervention: Telephone-delivered physical activity and dietary behavior change intervention
Number of subjects: 0
Study: 18644587

Group type: EXPERIMENTAL
Intervention: Idiomatic phrasal verbs
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Nonidiomatic phrasal verbs
Number of subjects: 0
Study: 17822464

Group type: EXPERIMENTAL
Intervention: Pudendal nerve stimulation (PNS)
Number of subjects: 22

Group type: EXPERIMENTAL
Intervention: Sacral nerve stimulation (SNS)
Number of subjects: 22